Administrative Core
行政核心
基本信息
- 批准号:10762288
- 负责人:
- 金额:$ 23.53万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-09-22 至 2028-08-31
- 项目状态:未结题
- 来源:
- 关键词:AddressAdvocateAntelopesCaliforniaCatchment AreaCellular biologyCity of Hope Comprehensive Cancer CenterClinicalClinical TrialsCollaborationsCommunicationCommunitiesCommunity OutreachComprehensive Cancer CenterCountyDataDevelopmentDisparityDoctor of MedicineDoctor of PhilosophyEconomicsEnsureEnvironmentEvaluationFarmFosteringFundingGrantGrowthIncubatorsIndividualLatinaLeadLeadershipLos AngelesMentorsMentorshipMissionMonitorNational Cancer InstituteNeighborhoodsNew York CityPilot ProjectsPoliciesPolicy DevelopmentsPoliticsPrincipal InvestigatorPublicationsReportingResearchResearch PersonnelResourcesSafetyScienceTherapeuticTimeToxicologyTrainingTranslational ResearchUnited StatesUnited States National Institutes of HealthUniversitiesWorkcancer health disparitycareerchimeric antigen receptor T cellsdisparity eliminationdiversity and inclusiondrug developmenteducation researchexperiencefrontierhealth disparityhuman subject protectionmeetingsmemberminority communitiesnext generationoutreachprofessorprogramsrural areatimeline
项目摘要
The Administrative Core is led by the U54’s Principal Investigators, Ernest Martinez, Ph.D. (PI, University of
California, Riverside [UCR]) and Victoria Seewaldt, M.D. (PI, City of Hope Comprehensive Cancer Center
[CoHCCC]). The overall mission of the Administrative Core is to facilitate the U54 UCR – CoH Comprehensive
Cancer Center (CoHCCC) U54 partnership by providing high-quality scientific leadership, administrative support,
and fiscal management. The Administrative core supports U54 planning, priority-setting, and implementation.
The Core will support the ability of the External Advisory Board (EAB), Internal Advisory Board (IAB), and
Community Advisory Board (CAB) to guide and provide advice and oversight of our U54. Our EAB members are
national leaders and lead their own P20 and U54 grants focusing on eliminating disparities. EAB leaders include
Robert Winn, M.D. (Massey Comprehensive Cancer Center), Laura Fejerman, Ph.D. (UC Davis), Lucio Miele,
M.D. (LSU), and Melissa Simon, Ph.D. (Lurie Comprehensive Cancer Center). Our IAB members are senior
leaders at both UCR and CoHCCC. IAB leaders from UCR include Dr. Kelechi Kalu, Ph.D. and Vice Provost and
Professor of Political Science; Dr. Frances Sladek, Professor of Cell Biology and Toxicology. IAB leaders from
CoHCCC include Steven Forman, Ph.D., CoHCCC leader of CAR-T cell therapeutics program and Beckman
Therapeutic Director; Linda Malkas, Ph.D., Dean of Translational Science and External Affairs. To ensure
mentorship of the next generation of U54 leaders, we include on our IAB, two early-stage investigators (ESIs)
serve on our IAB, this includes Jernej Murn, Ph.D., a basic investigator from UCR and Ana Tergas, M.D., a
promising clinical trialist and Latina researcher from CoHCCC. Together, we will work with the Planning and
Evaluation Core (PEC) and serve as the U54’s oversight body. The IAB will meet with U54 leaders twice-year -
or more frequently if needed - to provide strategic direction, policy development, and evaluation of our U54
Partnership Projects and Cores. The PEC, IAB, and EAB will perform yearly review of Full and Pilot projects and
Cores. The CAB will evaluate projects and cores – particularly our Community Outreach Core and assess our
ability to mentor and promote the careers of URM ESI. The EAB, IAB, and CAB will meet jointly with U54 project
and core leaders to assess overall progress and ability to impact cancer health disparities and disparities in drug
development and clinical trials.
行政核心由U 54的主要研究员Ernest Martinez博士领导。(PI大学,
加州,滨江[UCR])和医学博士维多利亚塞瓦尔特。(PI City of Hope综合癌症中心
[CoHCCC])。行政核心的总体使命是促进U 54 UCR-CoH综合
癌症中心(CoHCCC)通过提供高质量的科学领导,行政支持,
和财政管理。行政核心支持U 54规划,优先事项的制定和实施。
核心将支持外部咨询委员会(EAB)、内部咨询委员会(IAB)和
社区咨询委员会(CAB)指导并提供建议和监督我们的U 54。我们的EAB成员是
国家领导人和领导自己的P20和U 54赠款,重点是消除差距。EAB领导人包括
Robert Winn,医学博士(梅西综合癌症中心),劳拉Fejerman,博士(UC Davis),Lucio Miele,
M.D. (LSU)Melissa Simon,Ph.D.(Lurie综合癌症中心)。我们的实验室成员
UCR和CoHCCC的领导人。来自UCR的IAB领导人包括博士Kelechi Kalu,博士。副教务长
政治学教授; Frances Sladek博士,细胞生物学和毒理学教授。IAB领导人从
CoHCCC包括Steven Forman博士,CAR-T细胞治疗项目的CoHCCC负责人和贝克曼
治疗主任;琳达Malkas博士,翻译科学和对外事务院长。确保
为了指导下一代U 54领导者,我们在IAB中包括两名早期研究人员(ESI)
在我们的实验室工作,包括杰纳·穆恩博士加州大学洛杉矶分校的基础调查员和Ana Tergas医学博士,一
有前途的临床试验者和来自CoHCCC的拉丁裔研究员。我们将与规划和
评估核心(PEC),并作为U 54的监督机构。IAB将每年两次与U 54领导人会面-
或在需要时更频繁地提供战略方向、政策制定和对U 54的评估
合作项目和核心。PEC、IAB和EAB将对全面和试点项目进行年度审查,
丹CAB将评估项目和核心-特别是我们的社区外展核心,并评估我们的
指导和促进URM ESI职业发展的能力。EAB、IAB和CAB将与U 54项目联合举行会议
和核心领导人评估整体进展和影响癌症健康差异和药物治疗差异的能力
开发和临床试验。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ERNEST MARTINEZ其他文献
ERNEST MARTINEZ的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ERNEST MARTINEZ', 18)}}的其他基金
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
1/2 药物开发和能力建设:UCR/CoH-CCC 合作伙伴关系
- 批准号:
10762157 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
2/2 药物开发和能力建设:UCR/CoH-CCC 合作伙伴关系
- 批准号:
10762287 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Role of MYC Acetylation in Oncogenic Transformation
MYC 乙酰化在致癌转化中的作用
- 批准号:
10159869 - 财政年份:2020
- 资助金额:
$ 23.53万 - 项目类别:
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (ADMIN-CORE)
2/2 药物开发和能力建设:UCR/CoH-CCC 合作伙伴关系 (ADMIN-CORE)
- 批准号:
10006593 - 财政年份:2019
- 资助金额:
$ 23.53万 - 项目类别:
2/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership (ADMIN-CORE)
2/2 药物开发和能力建设:UCR/CoH-CCC 合作伙伴关系 (ADMIN-CORE)
- 批准号:
10469598 - 财政年份:2019
- 资助金额:
$ 23.53万 - 项目类别:
1/2 Drug Development and Capacity Building: A UCR/CoH-CCC Partnership
1/2 药物开发和能力建设:UCR/CoH-CCC 合作伙伴关系
- 批准号:
10006525 - 财政年份:2019
- 资助金额:
$ 23.53万 - 项目类别:
相似海外基金
Optimizing Health and Well-Being of Diverse Mothers with IDD and Their Infants During the Perinatal Period: A Virtual Advocate Tool for Data-Driven Supports
优化患有 IDD 的不同母亲及其婴儿在围产期的健康和福祉:用于数据驱动支持的虚拟倡导工具
- 批准号:
10760051 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
POSE: Phase II: Advocate Led Long-term Gameplan for Open OnDemand (ALL GOOD)
POSE:第二阶段:倡导者主导 Open OnDemand 的长期游戏计划(一切顺利)
- 批准号:
2303692 - 财政年份:2023
- 资助金额:
$ 23.53万 - 项目类别:
Standard Grant
Capitalising on our differences: A gathering to better understand and advocate for Early Career Health Researchers in Canada
利用我们的差异:更好地理解和倡导加拿大早期职业健康研究人员的聚会
- 批准号:
468168 - 财政年份:2022
- 资助金额:
$ 23.53万 - 项目类别:
Miscellaneous Programs
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10427960 - 财政年份:2022
- 资助金额:
$ 23.53万 - 项目类别:
Evaluating an ACEs-Targeting Advocate Model of a Substance Use Prevention Program
评估药物使用预防计划的针对 ACE 的倡导者模型
- 批准号:
10577074 - 财政年份:2022
- 资助金额:
$ 23.53万 - 项目类别:
The Art of Creation: Using Art-Based Knowledge Translation to Promote and Advocate for a Healthy Start to Life
创造的艺术:利用基于艺术的知识转化来促进和倡导健康的生命开端
- 批准号:
486588 - 财政年份:2022
- 资助金额:
$ 23.53万 - 项目类别:
Studentship Programs
When I am Old, I shall Wear Purple Nail Varnish: Utilising performance art to construct queer spaces that celebrate and advocate for ageing bodies
当我老了,我要涂紫色指甲油:利用行为艺术构建酷儿空间,庆祝和倡导衰老的身体
- 批准号:
2760091 - 财政年份:2022
- 资助金额:
$ 23.53万 - 项目类别:
Studentship
Addressing social adversity to improve outcomes among children undergoing liver transplant: the role for a health advocate on the transplant team
解决社会逆境以改善接受肝移植的儿童的预后:移植团队中健康倡导者的作用
- 批准号:
10621188 - 财政年份:2022
- 资助金额:
$ 23.53万 - 项目类别:
Techquity by FAITH!: A cluster randomized controlled trial to assess the efficacy of a community-informed, cardiovascular health promotion mobile hlth intervention with digital health advocate support
Techquity by FAITH!:一项整群随机对照试验,旨在评估社区知情、心血管健康促进移动 hlth 干预措施在数字健康倡导者支持下的效果
- 批准号:
10891016 - 财政年份:2021
- 资助金额:
$ 23.53万 - 项目类别:
CMV responses in autoantibody positive subjects advocate antiviral treatments for prevention of T1D
自身抗体阳性受试者的 CMV 反应主张抗病毒治疗以预防 T1D
- 批准号:
10230365 - 财政年份:2020
- 资助金额:
$ 23.53万 - 项目类别: